The Roles of Lysosomes in Inflammation and Autoimmune Diseases

International Reviews of Immunology

Volumn 34, Issue 5, 2015, Pages 415-431

  Ge, Wei ^a   Li, Dongxu ^b   Gao, Yanpan ^a   Cao, Xuetao ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

autoimmune diseases; cytokines; inflammation; lysosome

Indexed keywords

AUTOANTIGEN; BETA INTERFERON; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROLASE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEMBRANE PROTEIN; PROTEINASE; RAB PROTEIN; RAB39A PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; HUMAN; INFLAMMATION; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; EXOCYTOSIS; IMMUNOLOGY; METABOLISM; PHAGOCYTOSIS;

AUTOIMMUNE DISEASES; CYTOKINES; EXOCYTOSIS; GLUCOCORTICOIDS; HUMANS; HYDROLASES; INFLAMMATION; INFLAMMATION MEDIATORS; LYSOSOMES; PHAGOCYTOSIS; RECEPTORS, GLUCOCORTICOID; SIGNAL TRANSDUCTION;

EID: 84941876008     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2014.936587     Document Type: Review

References (97)

1. Carlstedt-Duke J, Wrange O, Dahlberg E, et al. Transformation of the glucocorticoid receptor in rat liver cytosol by lysosomal enzymes. J Biol Chem 1979;254:1537-1539.
2. Vandevyver S, Dejager L, Libert C. On the trail of the glucocorticoid receptor: into the nucleus and back. Traffic 2012;13:364-374.
3. Kassel O, Herrlich P. Crosstalk between the glucocorticoid receptor and other transcription factors: molecular aspects.Mol Cell Endocrinol 2007;275:13-29.
4. Vandevyver S, Dejager L, Tuckermann J, et al. New insights into the anti-inflammatory mechanisms of glucocorticoids: an emerging role for glucocorticoid-receptor-mediated transactivation. Endocrinology 2013;154:933-1007.
5. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs.N Engl JMed 2005;353:1711-1723.
6. Tanaka J, Fujita H, Matsuda S, et al. Glucocorticoid- and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Glia 1997;20:23-37.
7. He Y, Xu Y, Zhang C, et al. Identification of a lysosomal pathway that modulates glucocorticoid signaling and the inflammatory response. Sci Signal 2011;4:ra44. doi: 10.1126/scisignal.2001450
8. Settembre C, Fraldi A,Medina DL, et al. Signals fromthe lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 2013;14:283-296.
9. Blott EJ, Griffiths GM. Secretory lysosomes. Nat RevMol Cell Biol 2002;3:122-131.
10. Andrei C,Dazzi C, Lotti L, et al.Thesecretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysosome-related vesicles.Mol Biol Cell 1999;10:1463-1475.
11. Becker CE, Creagh EM,O'Neill LA. Rab39a binds caspase-1 and is required for caspase-1-dependent interleukin-1beta secretion. J Biol Chem 2009;284:34531-34537.
12. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-550.
13. Eder C.Mechanisms of interleukin-1 beta release. Immunobiology 2009;214:543-553.
14. Andrei C,Margiocco P, Poggi A, et al. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci USA 2004;101:9745-9750.
15. Carta S, Tassi S, Semino C, et al. Histone deacetylase inhibitors prevent exocytosis of interleukin- 1beta-containing secretory lysosomes: role of microtubules. Blood 2006;108:1618-1626.
16. Stow JL, Murray RZ. Intracellular trafficking and secretion of inflammatory cytokines. Cytokine Growth Factor Rev 2013;24:227-239.
17. Holt OJ, Gallo F, Griffiths GM. Regulating secretory lysosomes. J Biochem 2006;140:7-12.
18. StowJL,Manderson AP,Murray RZ. SNAREing immunity: the role of SNAREs in the immune system. Nat Rev Immunol 2006;6:919-929.
19. Li J, YinHL, Yuan J. Flightless-I regulates proinflammatory caspases by selectively modulating intracellular localization and caspase activity. J Cell Biol 2008;181:321-333.
20. Lei N, Franken L, Ruzehaji N, et al. Flightless, secreted through a late endosome/lysosome pathway, binds LPS and dampens cytokine secretion. J Cell Sci 2012;125:4288-4296.
21. Gardella S, Andrei C, Poggi A, et al. Control of interleukin-18 secretion by dendritic cells: role of calcium influxes. FEBS Lett 2000;481:245-248.
22. Semino C, Angelini G, Poggi A, et al. NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DCmaturation factor HMGB1. Blood 2005;106:609-616.
23. Lahat N, Rahat MA, Kinarty A, et al. Hypoxia enhances lysosomal TNF-alpha degradation in mouse peritonealmacrophages. AmJ Physiol Cell Physiol 2008;295:C2-12.
24. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl JMed 2011;364:656-665.
25. Bastow ER, Last K, Golub S, et al. Evidence for lysosomal exocytosis and release of aggrecandegrading hydrolases from hypertrophic chondrocytes, in vitro and in vivo. Biol Open 2012;1:318-328.
26. Pushparaj PN, Tay HK, Wang CC, et al. VAMP8 is essential in anaphylatoxin-induced degranulation, TNF-alpha secretion, peritonitis, and systemic inflammation. J Immunol 2009;183:1413- 1418.
27. Antonin W, Holroyd C, Tikkanen R, et al. The R-SNARE endobrevin/VAMP-8 mediates homotypic fusion of early endosomes and late endosomes.Mol Biol Cell 2000;11:3289-3298.
28. Advani RJ, Yang B, Prekeris R, et al. VAMP-7 mediates vesicular transport from endosomes to lysosomes. J Cell Biol 1999;146:765-776.
29. Dodeller F, Gottar M, Huesken D, et al. The lysosomal transmembrane protein 9B regulates the activity of inflammatory signaling pathways. J Biol Chem 2008;283:21487-21494.
30. Wang Y, Chen T, Han C, et al. Lysosome-associated small Rab GTPase Rab7b negatively regulates TLR4 signaling in macrophages by promoting lysosomal degradation of TLR4. Blood 2007;110:962-971.
31. YaoM, Liu X, Li D, et al. Late endosome/lysosome-localized Rab7b suppresses TLR9-initiated proinflammatory cytokine and type I IFN production inmacrophages. J Immunol 2009;183:1751-1758.
32. He D, Chen T, Yang M, et al. Small Rab GTPase Rab7b promotes megakaryocytic differentiation by enhancing IL-6 production and STAT3-GATA-1 association. JMolMed (Berl) 2011;89:137-150.
33. German CL, Sauer BM, Howe CL.TheSTAT3 beacon: IL-6 recurrently activates STAT 3 from endosomal structures. Exp Cell Res 2011;317:1955-1969.
34. Tanaka Y, Tanaka N, Saeki Y, et al. c-Cbl-dependentmonoubiquitination and lysosomal degradation of gp130.Mol Cell Biol 2008;28:4805-4818.
35. Radtke S, Wüller S, Yang XP, et al. Cross-regulation of cytokine signalling: pro-inflammatory cytokines restrict IL-6 signalling through receptor internalisation and degradation. J Cell Sci 2010;123:947-959.
36. Hao X, Wang Y, Ren F, et al. SNX25 regulates TGF-beta signaling by enhancing the receptor degradation. Cell Signal 2011;23:935-946.
37. Tian H, Mythreye K, Golzio C, et al. Endoglin mediates fibronectin/alpha5beta1 integrin and TGFbeta pathway crosstalk in endothelial cells. EMBO J 2012;31:3885-3900.
38. Iyer JK, Khurana T, Langer M, et al. Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking. Infect Immun 2010;78:2418-2428.
39. Hakala JK, Lindstedt KA, Kovanen PT, et al. Low-density lipoprotein modified by macrophagederived lysosomalhydrolases induces expression and secretion of IL-8 via p38MAPKandNF-kappaB by humanmonocyte-derivedmacrophages. ArteriosclerThromb Vasc Biol 2006;26:2504-2509.
40. Chinenov Y, Gupte R, Rogatsky I. Nuclear receptors in inflammation control: repression by GR and beyond.Mol Cell Endocrinol 2013;380:55-64.
41. Castaneda JA, Lim MJ,Cooper JD, et al. Immune system irregularities in lysosomal storage disorders. Acta Neuropathol 2008;115:159-174.
42. Darmoise A, Teneberg S, Bouzonville L, et al. Lysosomal alpha-galactosidase controls the generation of self lipid antigens for natural killer T cells. Immunity 2010;33:216-228.
43. Hsing LC, Rudensky AY.The lysosomal cysteine proteases in MHC class II antigen presentation. Immunol Rev 2005;207:229-241.
44. Neefjes J, JongsmaML, Paul P, et al. Towards a systems understanding ofMHCclass I andMHC class II antigen presentation. Nat Rev Immunol 2011;11:823-836.
45. ChowA, Toomre D,GarrettW, et al.Dendritic cellmaturation triggers retrogradeMHCclass II transport fromlysosomes to the plasma membrane. Nature 2002;418:988-994.
46. Kis-Toth K, TsokosGC.Dendritic cell function in lupus: Independent contributors or victims of aberrant immune regulation. Autoimmunity 2010;43:121-130.
47. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006;6:823-835.
48. Gaipl US, Kuhn A, Sheriff A, et al. Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 2006;9:173-187.
49. Odaka C,Mizuochi T. Role ofmacrophage lysosomal enzymes in the degradation of nucleosomes of apoptotic cells. J Immunol 1999;163:5346-5352.
50. Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells. Cell 2010;140:619-630.
51. Su DL, Lu ZM, Shen MN, et al. Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol 2012;2012:347141.
52. Ronnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol 2010;6:339-347.
53. Holcombe RF, Baethge BA, Wolf RE, et al. Correlation of serum interleukin-8 and cell surface lysosome-associated membrane protein expression with clinical disease activity in systemic lupus erythematosus. Lupus 1994;3:97-102.
54. HiraokaM, Abe A, Shayman JA. Cloning and characterization of a lysosomal phospholipase A2, 1-Oacylceramide synthase. J Biol Chem 2002;277:10090-10099.
55. Abe A, Shayman JA. Purification and characterization of 1-O-acylceramide synthase, a novel phospholipase A2 with transacylase activity. J Biol Chem 1998;273:8467-8474.
56. Shayman JA, Kelly R, Kollmeyer J, et al. Group XV phospholipase A(2), a lysosomal phospholipase A(2). Prog Lipid Res 2011;50:1-13.
57. Shayman JA, Abe A, Kelly R, et al., inventors; The Regents Of The University Of Michigan, assignee. Lysosomal phospholipase A2 (LPLA2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis. United States patent US8052970 B2. 2009 Jun 30, 2009.
58. Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity 2004;20:539-550.
59. Wallace DJ,Gudsoorkar VS,WeismanMH, et al.New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 2012;8:522-533.
60. Everts V, Hou WS, Rialland X, et al. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif Tissue Int 2003;73:380-386.
61. Hou WS, Li Z, Gordon RE, et al. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. AmJ Pathol 2001;159:2167-2177.
62. Skoumal M, Haberhauer G, Kolarz G, et al. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis ResTher 2005;7:R65-70.
63. Morko J, Kiviranta R, Joronen K, et al. Spontaneous development of synovitis and cartilage degeneration in transgenicmice overexpressing cathepsin K. Arthritis Rheum 2005;52:3713-3717.
64. Schurigt U, Hummel KM, Petrow PK, et al. Cathepsin K deficiency partially inhibits, but does not prevent, bone destruction in human tumor necrosis factor-transgenic mice. Arthritis Rheum 2008;58:422-434.
65. Li P, Schwarz EM.TheTNF-alpha transgenicmouse model of inflammatory arthritis. Springer Semin Immunopathol 2003;25:19-33.
66. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. BioorgMed Chem Lett 2008;18:923-928.
67. Svelander L, Erlandsson-Harris H, Astner L, et al. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. Eur J Pharmacol 2009;613:155-162.
68. Sun P, Liu Y, Deng X, et al. An inhibitor of cathepsin K, icariin suppresses cartilage and bone degradation in mice of collagen-induced arthritis. Phytomedicine 2013;20:975-979.
69. Nakagawa TY, Brissette WH, Lira PD, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10:207-217.
70. Pozgan U, Caglic D, Rozman B, et al. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem 2010;391:571-579.
71. Weidauer E, Yasuda Y, Biswal BK, et al. Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S. Biol Chem 2007;388: 331-336.
72. Baugh M, Black D, Westwood P, et al. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease inmodels of autoimmunity. J Autoimmun 2011;36:201-209.
73. Schurigt U, Eilenstein R, Gajda M, et al. Decreased arthritis severity in cathepsin L-deficient mice is attributed to an impaired T helper cell compartment. Inflamm Res 2012;61:1021-1029.
74. Schedel J, Seemayer CA, Pap T, et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. GeneTher 2004;11:1040-1047.
75. Pancewicz S, Popko J, Rutkowski R, et al. Activity of lysosomal exoglycosidases in serumand synovial fluid in patients with chronic Lyme and rheumatoid arthritis. Scand J Infect Dis 2009;41:584-589.
76. Boyce BF, Li P, Yao Z, et al. TNF-alpha and pathologic bone resorption. Keio JMed 2005;54:127-131.
77. Connor AM, Mahomed N, Gandhi R, et al. TNFalpha modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts. Arthritis ResTher 2012;14:R62.
78. Lin NY, Beyer C, Giessl A, et al. Autophagy regulates TNFalpha-mediated joint destruction in experimental arthritis. Ann Rheum Dis 2013;72:761-768.
79. Tanaka Y, Matsumoto I, Iwanami K, et al. Six-transmembrane epithelial antigen of prostate4 (STEAP4) is a tumor necrosis factor alpha-induced protein that regulates IL-6, IL-8, and cell proliferation in synovium frompatients with rheumatoid arthritis.Mod Rheumatol 2012;22:128-136.
80. Vijayan V, Shyni GL, Helen A. Efficacy of Bacopa monniera (L.)Wettst in alleviating lysosomal instability in adjuvant-induced arthritis in rats. Inflammation 2011;34:630-638.
81. Ekambarama SP, Perumala SS, Subramanianb V. Strychnos potatorum Linn Seed Extract Enhances Lysosomal Membrane Stability and Collagen Formation in Freunds Complete Adjuvant-Induced Arthritic Rats. J Herbs SpicesMed Plants 2011;17:392-402.
82. Kawada A, Hara K, Kominami E, et al. Processing of cathepsins L, B and D in psoriatic epidermis. Arch Dermatol Res 1997;289:87-93.
83. Abdou AG, Maraee AH, Shoeib MA, et al. Cathepsin D expression in chronic plaque psoriasis: an immunohistochemical study. Acta Dermatovenerol Croat 2011;19:143-149.
84. Schonefuss A, Wendt W, Schattling B, et al. Upregulation of cathepsin S in psoriatic keratinocytes. Exp Dermatol 2010;19:e80-88.
85. Higaki M, Higaki Y, Kawashima M. Increased expression of CD208 (DC-LAMP) in epidermal keratinocytes of psoriatic lesions. J Dermatol 2009;36:144-149.
86. Wei-yuan M,Wen-ting L, Chen Z, et al. Significance of DC-LAMP and DC-SIGN expression in psoriasis vulgaris lesions. ExpMol Pathol 2011;91:461-465.
87. Haves-Zburof D, Paperna T, Gour-Lavie A, et al. Cathepsins and their endogenous inhibitors cystatins: expression and modulation inmultiple sclerosis. J CellMolMed 2011;15:2421-2429.
88. Martino S, Montesano S, di Girolamo I, et al. Expression of cathepsins S and D signals a distinctive biochemical trait in CD34+ hematopoietic stem cells of relapsing-remitting multiple sclerosis patients. Mult Scler 2013;19:1443-1453.
89. Sohar N, Sohar I, Hammer H. Lysosomal enzyme activities: new potentialmarkers for Sjogren's syndrome. Clin Biochem 2005;38:1120-1126.
90. Li X, Wu K, Edman M, et al. Increased expression of cathepsins and obesity-induced proinflammatory cytokines in lacrimal glands ofmaleNOD mouse. Invest Ophthalmol Vis Sci 2010;51:5019-5029.
91. Komosinska-Vassev K, Olczyk K, Kozma EM, et al. Graves' disease-associated changes in the serum lysosomal glycosidases activity and the glycosaminoglycan content.ClinChimActa 2003;331:97-102.
92. Chen MH, Liao SL, Chen MH, et al. Lysosome-related genes are regulated in the orbital fat of patients with graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2008;49:4760-4764.
93. Wong VW, Saunders AE, Hutchings A, et al. The autoimmunity-related GIMAP5 GTPase is a lysosome-associated protein. Self Nonself 2010;1:259-268.
94. Yamada A, Ishimaru N, Arakaki R, et al. Cathepsin L inhibition prevents murine autoimmune diabetes via suppression of CD8(+) T cell activity. PLoS One 2010;5:e12894.
95. Hsing LC, Kirk EA,McMillen TS, et al. Roles for cathepsins S, L, and B in insulitis and diabetes in the NODmouse. J Autoimmun 2010;34:96-104.
96. Zou F, Schafer N, Palesch D, et al. Regulation of cathepsin G reduces the activation of proinsulinreactive T cells from type 1 diabetes patients. PLoS One 2011;6:e22815. doi: 10.1371/journal. pone.0022815
97. WerneburgN,Guicciardi ME, Yin XM, et al. TNF-alpha-mediated lysosomal permeabilization is FAN and caspase 8/Bid dependent. Am J Physiol Gastrointest Liver Physiol 2004;287:G436-443.